Astellas invests $50 million in Taysha Gene Therapies
Taysha will license AAV gene therapy candidates TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy to Astellas.
List view / Grid view
News
$3 trillion growth reported for biotech sector
A report reveals US job growth in the biotech industry has risen 11 percent since 2018, tipping the COVID-19 pandemic as the key driver.
NICE recommends first oral GnRH antagonist for uterine fibroids
Ryeqo, a one-per-day oral drug for adults with moderate-to-severe symptoms of uterine fibroids has been given the green light by NICE.
University of Oklahoma to open bioprocessing training facility
The centre will help prepare engineers and advance research in this emerging industry, according to Gallogly College of Engineering’s Associate Dean for Research.
ITM licenses targeted radionuclide therapy candidate
The targeted radionuclide therapy for glioblastoma is administered into a tumour cavity via a reservoir post-surgery and standard post-operative therapy.
ADC developers opt to outsource
Most developers of antibody drug conjugates choose to outsource operations to mitigate manufacturing challenges, says report.
AstraZeneca dual immunotherapy approved for US liver cancer patients
The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
Vaccine producers promise equal access in future pandemics
COVID-19 vaccine key players back a new proposal ensuring vaccines for future pandemics are equally distributed to all priority populations.
UK research consortium given £2 million to control monkeypox
£2 million will help fund a UK team of scientific experts to research monkeypox, uncover novel treatments and curb the spread of the virus.
Steep drop for UK industry clinical trials between 2017 and 2021
COVID-19 has accelerated the decline in late-stage industry clinical research in the UK, compared to its global peers.
Three-dose vaccine prevents HIV patients getting hepatitis B
Clinical trial results suggest adult HIV patients can be protected against hepatitis B with a three-dose vaccine series.
Gilead and MacroGenics to develop bispecific cancer antibodies
A collaboration agreement between Gilead and biopharma company MacroGenics aims to develop MGD024, a bispecific antibody for treatment of blood cancers.
Shingles vaccine offers a decade of protection in older adults
Shingrix can effectively vaccinate adults over 50 years old against shingles for at least 10 years, new data shows.
First patient receives novel, potentially cancer-stopping pill
City of Hope has developed AOH1996, a promising cancer medicine, for people with reoccurring solid tumours.
Immunotherapy shows benefits for hospitalised COVID-19 patients
Apogenix’s asunercept demonstrates efficacy in Phase II trial for the treatment of hospitalised COVID-19 patients.
